Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

38

Revenue 2017

Imbruvica

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Imbruvica was produced by Johnson & Johnson.

Sanofi licences Principia MS drug in $805m deal

Sanofi licences Principia MS drug in $805m deal BTK is best known as the target for Johnson/AbbVie's big-selling blood cancer therapy Imbruvica (ibrutinib) and AstraZeneca’s recently-approved rival Calquence (acalabrutinib).

AZ gets early FDA green light for Imbruvica challenger

AZ gets early FDA green light for Imbruvica challenger The new product - which will be sold in the US as Calquence - has been approved much earlier than expected, bringing forward a marketing battle with Johnson/AbbVie's big-selling Imbruvica ... The new product will launch with a list price of around $14,

J&J files would-be prostate cancer blockbuster in US

J&J files would-be prostate cancer blockbuster in US That view was echoed by Jefferies Jeffrey Holford, who says J&J’s so-called TIRADE products - Tremfya (guselkumab) for psoriasis, cancer drug Imbruvica (ibrutinib), anticoagulant rivaroxaban (Xarelto), apalutamide, Darzalex (daratumumab)

Janssen's Imbruvica fails to win NICE backing in lymphoma

Janssen's Imbruvica fails to win NICE backing in lymphoma Janssen received mixed news from NICE on its first-in-class BTK inhibitor Imbruvica (ibrutinib) this week. ... There was some positive news for Janssen, however, as Imbruvica received a positive recommendation to treat Waldenström's Macroglobulinaemia

AbbVie deal with Amgen sets biosimilar Humira launch dates

AbbVie deal with Amgen sets biosimilar Humira launch dates for new launches such as blood cancer therapies Imbruvica (ibrutinib) and Venclexta (venetoclax).

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....

Infographics